statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals...

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Federated Hermes Inc. decreased its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR  Free Report) by 0.8% during the 3rd quarter, according to the company in its most recent 13F filing with...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Federated Hermes Inc.

Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript...

Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript

Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400...

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ( Atea ), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR  Free Report)  Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Atea Pharmaceuticals in a research note...

Q1 2024 Earnings Forecast for Atea Pharmaceuticals, Inc. Issued By Leerink Partnrs (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR  Free Report)  Analysts at Leerink Partnrs reduced their FY2023 earnings per share (EPS) estimates for Atea Pharmaceuticals in a report released...

Leerink Partnrs Research Analysts Decrease Earnings Estimates for Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR  Free Report)  Investment analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for shares of Atea Pharmaceuticals in a report...

Atea Pharmaceuticals, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.66) Per Share (NASDAQ:AVIR)

SG Americas Securities LLC bought a new position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR  Free Report) in the third quarter, according to its most recent filing with the Securities and...

SG Americas Securities LLC Acquires New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study Phase 3 SUNRISE-3 Enrollment Surpassed 650...

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Watchers	3,179
52-Wk Low	$2.77
52-Wk High	$5.19

Volume	231,367.00
52-Wk High	$5.19
52-Wk Low	$2.77

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.66	--	--	N/A
Q1'24	-$0.53	-$0.75	-41.51%	MISSED
Q4'23	-$0.43	-$0.47	-8.71%	MISSED
Q3'23	-$0.46	-$0.40	13.50%	BEAT
Q2'23	-$0.47	-$0.34	27.64%	BEAT

AVIR Atea Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals